ArticleOncotarget2015
Expression and clinicopathological significance of FSIP1 in breast cancer.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- The FSIP Family: Roles in Health and Cancer.Cancers · 2025Review
- Elevated mRNA level indicates FSIP1 promotes EMT and gastric cancer progression by regulating fibroblasts in tumor microenvironment.Open medicine (Warsaw, Poland) · 2024Article
- FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway.Science China. Life sciences · 2023Article
- FSIP1 Is Associated with Poor Prognosis and Can Be Used to Construct a Prognostic Model in Gastric Cancer.Disease markers · 2022Article
- Clinical significance of expression of fibrous sheath interacting protein 1 in colon cancer.World journal of gastrointestinal oncology · 2020Article
- RNA-seq analysis identified hormone-related genes associated with prognosis of triple negative breast cancer.Journal of biomedical research · 2020Article
- FSIP1 regulates autophagy in breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Absence of AIF1L contributes to cell migration and a poor prognosis of breast cancer.OncoTargets and therapy · 2018Article
- Knockdown of fibrous sheath interacting protein 1 expression reduces bladder urothelial carcinoma cell proliferation and induces apoptosis via inhibition of the PI3K/AKT pathway.OncoTargets and therapy · 2018Article
- Article
- FSIP1 binds HER2 directly to regulate breast cancer growth and invasiveness.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Genetic diagnosis of a Chinese multiple endocrine neoplasia type 2A family through whole genome sequencing.Journal of biosciences · 2017Article
- Elevated fibrous sheath interacting protein 1 levels are associated with poor prognosis in non-small cell lung cancer patients.Oncotarget · 2017Article
- Fibrous sheath interacting protein 1 overexpression is associated with unfavorable prognosis in bladder cancer: a potential therapeutic target.OncoTargets and therapy · 2017Article
- Ectopic Expression of Testis Germ Cell Proteins in Cancer and Its Potential Role in Genomic Instability.International journal of molecular sciences · 2016Review
- Analysis of TRRAP as a Potential Molecular Marker and Therapeutic Target for Breast Cancer.Journal of breast cancer · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the clinicopathological significance of the expression of fibrous sheath interacting protein 1 (FSIP1) in breast cancer, serum samples, and wound fluid from patients with breast cancer.
methodsWound fluid and serum samples from female patients with primary breast cancer, recurrent and metastatic breast cancer, and benign tumors were analyzed for FSIP1 expression using ELISA. 286 paraffin-embedded surgical specimens from breast cancer patients with at least 5 years of follow-up were included for FSIP1 expression assay using immunohistochemistry.
resultsExpression of FSIP1 protein was significantly higher in breast cancer tissues compared to tumor-adjacent tissues (p = 0.001). Strong correlation was observed between FSIP1 expression and human epidermal growth factor receptor 2 (Her-2) or Ki67 expression in breast cancer (p = 0.027 and 0.002, respectively). Similarly, serum level of FSIP1 was higher in patients with recurrent and metastatic breast cancer compared to that of primary breast cancer (7, 713 ± 3, 065 vs. 4, 713 ± 3, 065 pg/ml, p = 0.003). Finally, patients with high FSIP1 expression showed a worse post-operative disease-specific survival (p = 0.024).
conclusionFSIP1 may play an important role in the tumorigenesis and invasion of breast cancer and is a potential biomarker for breast cancer diagnosis or prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.